Team Leader in Drug Discovery Biology

Ref: 5477

The Institute of Cancer Research


Apply Now

Role Managed by:

Alex Hurlow

Research Associate

t: +44 (0)20 7340 6282


Primary Practice Group: Higher Education and Research

Salary & Benefits: Competitive

Closing Date: 31/01/2022

Formal Interview Date: April 2022

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes with an outstanding track record of achievement dating back more than 100 years. Our mission is to make the discoveries that defeat cancer, which we seek to achieve through world-leading research and internationally excellent learning and teaching.

Today, The Institute of Cancer Research (ICR) is rated as the UK’s leading higher education institution for the quality and impact of our research. We are world leaders in the identification of cancer-related genes, discovery of new targeted cancer drugs and development of new forms of high-precision radiotherapy. Our unique partnership with The Royal Marsden NHS Foundation Trust and integrated 'bench to bedside and back again’ approach ensure our research advances rapidly reach patients and place us among the top four centres in the world for cancer research and treatment.

The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. The Division houses the Cancer Therapeutics Unit (CTU) as one of the largest academic cancer drug discovery groups in the world. With our collaborators, the CTU has discovered 20 preclinical development candidates since 2005, 11 of which have been progressed to clinical evaluation. Our drug abiraterone (Zytiga) has been approved in the US, Canada, and Europe for late-stage prostate cancer.

The ICR is now seeking a cancer biologist with a track record of success to lead an independent cancer biology research group that contributes to the overall strategy and goals of the Division and the CTU; in particular, progression of innovative small molecule anticancer compounds to proof-of-concept clinical trials. The successful candidate will be committed to translational and drug discovery research and will apply molecular pharmacology and cancer biology approaches to support hypothesis-driven target validation decisions, implement functional and mechanistic assays to support progression of potential small molecule therapeutics, and develop and test hypotheses regarding patient selection strategies. It will be critical to demonstrate intellectual leadership and the ability to personally lead a laboratory research team. Experience of drug discovery and translating drug discoveries to the clinic in a pharma or biotechnology company would be highly desirable.

The ICR has engaged Perrett Laver to support the Appointment Panel for this role. For informal enquiries about the role please contact Dr Alex Hurlow at or +44 (0)20 7340 6282.

The closing date for applications is at 9am (GMT) on Monday 31st January 2022. Final stage interviews will take place in April 2022.


For a conversation in confidence, please contact Dr Alex Hurlow at or +44 (0)20 7340 6282.

Should you require access to these documents in alternative formats, please contact Lina Franzen on

If you have comments that would support us to improve access to documentation, or our application processes more generally, please do not hesitate to contact us via

Data Protection and Privacy

Protecting your personal data is of the utmost importance to Perrett Laver and we take this responsibility very seriously. Any information obtained by our trading divisions is held and processed in accordance with the relevant data protection legislation. The data you provide us with is securely stored on our computerised database and transferred to our clients for the purposes of presenting you as a candidate and/or considering your suitability for a role you have registered interest in.

As defined under the General Data Protection Regulation (GDPR) Perrett Laver is a Data Controller and a Data Processor, and our legal basis for processing your personal data is ‘Legitimate Interests’.  You have the right to object to us processing your data in this way. For more information about this, your rights, and our approach to Data Protection and Privacy, please visit our website